{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:54:39Z","timestamp":1792580079700,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"DOI":"10.7759\/cureus.55324","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T12:10:16Z","timestamp":1709295016000},"source":"Crossref","is-referenced-by-count":6,"title":["Semaglutide-Induced Lupus Erythematosus With Multiorgan Involvement"],"prefix":"10.7759","author":[{"given":"Vanessa","family":"Castellanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiwot","family":"Workneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000522","article-title":"Drug-induced lupus erythematosus: an update on drugs and mechanisms","volume":"30","author":"He Y","year":"2018","unstructured":"He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018, 30:490-497. 10.1097\/BOR.0000000000000522","journal-title":"Curr Opin Rheumatol"},{"key":"ref2","article-title":"Drug-Induced Lupus Erythematosus","author":"Solhjoo M","year":"2023","unstructured":"Solhjoo M, Goyal A, Chauhan K. Drug-Induced Lupus Erythematosus. StatPearls, Treasure Island; 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice Parameters","year":"2010","unstructured":"Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, & Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010, 105:259-273. 10.1016\/j.anai.2010.08.002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref4","unstructured":"Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA. (2023). https.\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutid...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.674","article-title":"Liraglutide-induced autoimmune hepatitis","volume":"174","author":"Kern E","year":"2014","unstructured":"Kern E, VanWagner LB, Yang GY, Rinella ME. Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014, 174:984-987. 10.1001\/jamainternmed.2014.674","journal-title":"JAMA Intern Med"},{"key":"ref6","article-title":"Drug-induced vasculitis: a clinical and pathological review","volume":"70","author":"Radi\u0107 M","year":"2012","unstructured":"Radi\u0107 M, Kaliterna DM, Radi\u0107 J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012, 70:12-17.","journal-title":"Neth J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f1331f","article-title":"Drug-induced vasculitis","volume":"20","author":"Wiik A","year":"2008","unstructured":"Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol. 2008, 20:35-39. 10.1097\/BOR.0b013e3282f1331f","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2016.62470","article-title":"Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art - part two","volume":"54","author":"Niklas K","year":"2016","unstructured":"Niklas K, Niklas AA, Majewski D, Puszczewicz MJ. Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art - part two. Reumatologia. 2016, 54:165-169. 10.5114\/reum.2016.62470","journal-title":"Reumatologia"},{"key":"ref9","article-title":"Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)","author":"Rodriguez WLKJLR","year":"2023","unstructured":"Rodriguez WLKJLR. Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls, Treasure Island; 2023."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_522_21","article-title":"A review of oral semaglutide available evidence: a new era of management of diabetes with peptide in a pill form","volume":"26","author":"Kalra S","year":"2022","unstructured":"Kalra S, Das S, Zargar AH. A review of oral semaglutide available evidence: a new era of management of diabetes with peptide in a pill form. Indian J Endocrinol Metab. 2022, 26:98-105. 10.4103\/ijem.ijem_522_21","journal-title":"Indian J Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez JJ","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al.. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022, 12:145. 10.3390\/jcm12010145","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2015","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2015, 11:202-230. 10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"ref13","unstructured":"Ozempic and Systemic lupus erythematosus, a phase IV clinical study of FDA data - eHealthMe . (2023). https.\/\/www.ehealthme.com\/ds\/ozempic\/systemic-lupus-erythematosus\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206746-semaglutide-induced-lupus-erythematosus-with-multiorgan-involvement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T12:10:20Z","timestamp":1709295020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206746-semaglutide-induced-lupus-erythematosus-with-multiorgan-involvement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.55324","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}